Biologically Active Substance
Novartis Acquires Anthos Therapeutics for $925M, Regaining Control of Promising Anticoagulant Abelacimab
Novartis, Anthos Therapeutics, acquisition, abelacimab, anticoagulant, Factor XI inhibitor, atrial fibrillation, stroke prevention, cardiovascular pipeline
Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor
Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma
Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders
DOGE Access to Treasury Systems Restricted Amid Concerns Over CMS Scrutiny
Elon Musk, DOGE, Treasury Department, CMS, payment systems, privacy concerns, lawsuit, federal court order
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
FDA Approves Vertex’s Journavx: A Breakthrough Non-Opioid Pain Medication
Journavx, suzetrigine, Vertex Pharmaceuticals, FDA approval, non-opioid pain reliever, acute pain treatment, NaV1.8 inhibitor
Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments
Sionna Therapeutics, IPO, cystic fibrosis, CFTR protein, NBD1 stabilizers, biotech, Nasdaq, clinical trials
Sionna Therapeutics Raises $191 Million in Upsized IPO for Cystic Fibrosis Drug Development
Sionna Therapeutics, cystic fibrosis, IPO, CFTR protein, NBD1 stabilizers, Vertex Pharmaceuticals, clinical trials
Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment
Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination
Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing
Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure